All News

02-09 Avacta appoints new chief scientific officer, plans clinical trials AN
02-09 Avacta Therapeutics Announces Executive Changes CI
01-30 Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BU
01-30 Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy AQ
01-29 Sector Update: Health Care Stocks Edge Higher Premarket Thursday MT
01-29 Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy CI
01-29 Summit Therapeutics Says US FDA Accepts BLA for Ivonescimab MT
01-29 Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy BU
01-13 AbbVie Enters Cancer Treatment Space via RemeGen Licensing Deal, UBS Says MT
01-12 Summit Therapeutics Inc. Announces Submission of Biologics License Application to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC CI
01-12 Summit Therapeutics Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 09:45 AM
01-12 Summit Therapeutics, GSK Team up on Clinical Trial for Combination Cancer Therapy MT
01-12 Summit Therapeutics Files Marketing Application for Lung Cancer Therapy MT
01-12 Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC) BU
01-12 Summit Therapeutics Announces Clinical Trial Collaboration with GSK plc to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate CI
01-12 Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC BU
01-10 Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BU
01-06 Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference BU
12-17 Barclays Upgrades Summit Therapeutics to Equal Weight From Underweight, Adjusts Price Target to $18 From $16 MT
12-09 Akeso, Inc. Announces Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia CI
12-05 Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BU
12-03 Summit Therapeutics Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 02:10 PM
12-02 Summit Therapeutics Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 10:30 AM
11-18 Summit Therapeutics Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 03:30 PM
11-10 Summit Therapeutics Inc. Presents at UBS Global Healthcare Conference 2025, Nov-10-2025 03:30 PM
No results for this search
  1. Stock Market
  2. Equities
  3. SMMT Stock
  4. News Summit Therapeutics Inc.